US · Healthcare · Drug Manufacturers - General
EPS came in at -6.75 against a street estimate of -7.07 — a beat of 4.5%.
Analysts rate Gilead Sciences Inc a buy (22 buy, 5 hold, 1 sell out of 28) with an average price target of $159.85.
CONFIDENT Gilead delivered 10% base business growth on HIV strength (especially PrEP at $4B run rate) and Trodelvy oncology gains. Raised FY26 guidance; expects 2 launches H2. Pipeline remains robust across HIV, liver disease, and oncology. Q2 2026 Europe contributing to Livdelzi uptake. Global data shared for islatravir/lenacapavir at IAS meeting in Brazil. Analysts pressed on Yeztugo–Descovy competitive dynamics, persistency drivers, and ISL/LEN cannibalization risks. Management emphasized market expansion, complementary positioning, and switch-market focus; no major cannibalization expected. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.83% |
| Vanguard Capital Management, LLC | 6.54% |
| FMR Inc | 5.39% |
| State Street Corp | 4.94% |
| Capital World Investors | 3.31% |
| Amvescap Plc. | 3.21% |
| Vanguard Portfolio Management, LLC | 2.85% |
| Geode Capital Management, LLC | 2.42% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 GILEAD SCIENCES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (6M 2026): $14,763 million vs. $13,749 million (6M 2025), +7.4% incre | 2026-08-06 |
| Results announced · Q3 2026 GILEAD SCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $7.8 billion, up 10% year-over-year • Q2 2026 Product Sales: $7. | 2026-08-04 |
| Material agreement · Q2 2026 GILEAD SCIENCES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued $3,000,000,000 in new senior notes across four tranches on May 20, 2026 • | 2026-05-20 |
| Quarterly report · Q1 2026 GILEAD SCIENCES, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $6,960 million (Q1 2025: $6,667 million) – up 4.4% • Product | 2026-05-07 |
| Results announced · Q2 2026 GILEAD SCIENCES Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Q1 2026 revenues: $7.0 billion, up 4% year-over-year • Product sales: $6.9 billion | 2026-05-07 |
| Shareholder vote results · Q2 2026 GILEAD SCIENCES, INC. – 2026 ANNUAL MEETING SUMMARY HEADLINE NUMBERS • Annual meeting held April 30, 2026 • Total shares entitled to vote: 1,241,222 | 2026-05-04 |
| Proxy statement · Q2 2026 GILEAD SCIENCES, INC. PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect nine director nominees to the Board (Annual Meetin | 2026-03-20 |
| Annual report FY2025 GILEAD SCIENCES, INC. - 2025 FORM 10-K SUMMARY --- HEADLINE NUMBERS • Market value of public float (as of last day of Q2 2025): $103.2 billion • Sh | 2026-02-24 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.82 / share ex-date Sep 15, 2026 · pay Sep 29, 2026 | 2026-09-15 |
| Dividend | $0.82 / share ex-date Jun 15, 2026 · pay Jun 29, 2026 | 2026-06-15 |
| Dividend | $0.82 / share ex-date Mar 13, 2026 · pay Mar 30, 2026 | 2026-03-13 |
| Dividend | $0.79 / share ex-date Dec 15, 2025 · pay Dec 30, 2025 | 2025-12-15 |
| Dividend | $0.79 / share ex-date Sep 15, 2025 · pay Sep 29, 2025 | 2025-09-15 |
| Announcement | Date |
|---|---|
| Completed acquisition of Arcellx, Inc. for $115 per share plus CVR Gilead Sciences completed its acquisition of Arcellx on April 28, 2026, for approximately $7.1 billion. Shareholders received $115 per share in cash plus one contingent value right (CVR) wor | 2026-04-28 |
| Gilead to acquire Arcellx for $115 per share plus contingent payments Gilead Sciences agreed to acquire Arcellx, Inc. for $115 per share in cash plus one contingent value right (CVR) worth up to $5 per share upon achieving a specified milestone. The total deal | 2026-02-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gilead Sciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.